Clinical trials: Varenicline
Cannabis Use Disorder
UH3 Varenicline for Cannabis Use Disorder
Marijuana is the most commonly used illicit drug. There is high demand for effective interventions for cannabis use disorder, yet few specific treatments for have been developed.
- Trial name
- NCT03980561
- Testing
- Varenicline
- Where
- 2 sites in United States
- Volunteers
- 174 people
- Sponsor
- Medical University of South Carolina
Chronic Obstructive Pulmonary Disease (COPD), Asthma
Combined Bio- and Neuro- Feedback vs. Varenicline Use for Smoking Cessation
This study will develop and experimentally test the efficiency of a neurofeedback training protocol vs. varenicline use for smoking cessation.
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Asthma, Smoking
- Trial name
- NCT02991781
- Testing
- Biofeedback and Neurofeedback Training, Varenicline use for smoking cessation, Passive Control
- Where
- 3 sites in Bulgaria, Cyprus and 1 more
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Aristotle University Of Thessaloniki
Nicotine Dependence
Measuring Smoking Behaviors While Using Varenicline
This study will demonstrate the behavioral responses to varenicline, helping to better understand its mechanisms. Hypotheses for the study are to observe decreases in smoking topography and nicotine cigarette choice on…
- Trial name
- NCT00948155
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Smoking Cessation, Bipolar Disorder
Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder
The investigators' hypothesis is that add-on varenicline will be effective (versus placebo) in initiating abstinence from smoking in subjects with stable, euthymic bipolar disorder who are motivated to quit smoking within four…
- Trial name
- BEST (NCT01010204)
- Testing
- Varenicline
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- K.N. Roy Chengappa
Dopamine D2/3 Receptor Availability, Cognitive Function
Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users
While deficits in dopamine D2-type receptor availability have been linked to substance use disorders, higher availability associates with better behavioral treatment outcomes for stimulant dependence and resilience to addiction.
- Conditions
- Dopamine D2/3 Receptor Availability, Cognitive Function, Methamphetamine Abuse
- Trial name
- NCT03059563
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of California, Los Angeles
Alcohol Use Disorder, Alcoholism
Varenicline and Bupropion for Alcohol Use Disorder
The COMB study is a randomized double-blind placebo-controlled multicenter trial in Sweden on the efficacy of varenicline and bupropion, in combination and alone, for treatment of alcohol use disorder (AUD).
- Conditions
- Alcohol Use Disorder, Alcoholism, Alcohol Dependence
- Trial name
- NCT04167306
- Testing
- Varenicline Tartrate 1 mg b.i.d, Bupropion Hydrochloride 150 mg b.i.d
- Where
- 4 sites in Sweden
- Volunteers
- 388 people, healthy volunteers welcome
- Sponsor
- Vastra Gotaland Region
Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use
This trial studies how well an enhanced tobacco intervention protocol (ETIP) works compared to standard treatment in helping head and neck and lung cancer patients starting treatment to reduce cigarette use.
- Trial name
- NCT04694846
- Testing
- Nicotine Replacement, Bupropion Hydrochloride Controlled-release, Varenicline
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Thomas Jefferson University
Cigarette Smoking
Smoking Interventions for Hospital Patients
Cigarette smoking is the leading preventable cause of death in the U.S. Nearly 4 million U.S. smokers are hospitalized each year, many of them at high risk for tobacco-related disease or death.
- Trial name
- Helping HAND (NCT01177176)
- Testing
- Extended Care Management, Standard Care
- Where
- United States
- Volunteers
- 397 people
- Sponsor
- Massachusetts General Hospital
Smokeless Tobacco, Nicotine Dependence
Treating Smokeless Tobacco Use in Rural Veterans
This is a pilot study designed in an effort to develop and improve access to effective treatments for tobacco use in rural Veterans using a tailored intervention approach.
- Trial name
- NCT02994082
- Testing
- Tailored behavioral intervention, Behavioral activation for elevated depressive symptoms, Post-cessation weight gain management
- Where
- United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Mark Vander Weg
Cerebrovascular Disorders, Smoking Cessation
Efficacy and Cost-Effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease
Research Aims The aims of this research study are to determine whether cost-free smoking cessation pharmacotherapy: 1. Helps smokers with Transient Ischemic Attack (TIA) or stroke to quit smoking over the long-term, compared to…
- Trial name
- NCT00962988
- Testing
- Cost-Free Pharmacotherapy Group, Prescription Only Group
- Where
- 2 sites in Canada
- Volunteers
- 194 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Schizophrenia, Schizoaffective Disorder
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
To test the feasibility of studying effects of smoking cessation with varenicline on antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of smoking cessation treatment with varenicline in 10…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia
- Trial name
- NCT03495024
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Smoking Cessation, Cancer
Tobacco Treatment Comparison for Cancer Care
This pilot comparative effectiveness trial will compare two active smoking cessation treatments in terms of effectiveness, equity across patient subpopulations, and efficiency among adult patients diagnosed with cancer within the…
- Trial name
- NCT06218823
- Testing
- Transdermal Nicotine Patch, Standard Telephone Counseling, Varenicline
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Wisconsin, Madison
Schizophrenia, Schizoaffective Disorder
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Varenicline (Chantix) is a smoking cessation treatment that was approved in 2006 by the FDA for treatment of nicotine dependence and may be particularly beneficial in smokers with schizophrenia or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
- Trial name
- SCRP (NCT00621777)
- Testing
- Varenicline
- Where
- 10 sites in United States
- Volunteers
- 247 people
- Sponsor
- Massachusetts General Hospital
Smoking Cessation
Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder
Study will determine whether patients with schizophrenia or schizoaffective disorder can be helped to quit smoking safely while using varenicline and receiving smoking cessation counseling.
- Trial name
- NCT00644969
- Testing
- varenicline (CP-526,555)
- Where
- 14 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- Pfizer
Smoking, Smoking Cessation
STARS (Smoking Treatment And Remote Sampling) Study
This is a research study to find out if a smoking cessation medications, either varenicline or nicotine replacement products (patches or lozenges), are effective when given to smokers, remotely, as a one-time sample.
- Conditions
- Smoking, Smoking Cessation, Tobacco Smoking, Cigarette Smoking
- Trial name
- NCT04525755
- Testing
- Varenicline 0.5 MG, Nicotine Replacement Therapy (NRT)
- Where
- United States
- Volunteers
- 652 people
- Sponsor
- Medical University of South Carolina
Smoking, Smoking Cessation
Preference-based Tools for Smoking Cessation Among Disadvantaged Smokers, a Pragmatic Randomised Controlled Trial
Objective: Our study aims to evaluate the effectiveness of the "STOP" (Sevrage Tabagique à l'aide d'Outils dédiés selon la Préférence: Smoking Cessation using preference-based tools) intervention, a preference-based smoking…
- Trial name
- STOP (NCT04654585)
- Testing
- The STOP intervention, Standard Care
- Where
- 15 sites in France
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- Société de Formation Thérapeutique du Généraliste - Recherche
Cigarette Smoking, Tobacco Use Disorder
Intervention Trial of Culturally-Appropriate Decision Aids for Smoking Cessation
Despite the establishment of various smoking cessation methods, including pharmacological intervention, only a small proportion of smokers who visit doctors choose to receive such assistance.
- Conditions
- Cigarette Smoking, Tobacco Use Disorder, Nicotine Dependence, Smoking Cessation
- Trial name
- NCT01566097
- Testing
- Smoking Cessation Decision Aids
- Where
- South Korea
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Tobacco Dependence, Smoking Cessation
Use of Varenicline for 4-weeks Prior to Quitting
Varenicline (Champix) is a relatively new medicine that is effective in helping people to quit smoking. It is normally started 1-week before stopping smoking and used for up to 12-24 weeks.
- Trial name
- NCT00789074
- Testing
- Varenicline
- Where
- United Kingdom
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Tobacco Use Disorder, Smoking Cessation
Pharmacogenetics, Emotional Reactivity and Smoking
The goals of this placebo-controlled randomized clinical trial were to evaluate the differences in emotional reactivity (peak startle response to affective stimuli) during a cessation attempt among smokers treated with bupropion…
- Trial name
- NCT00507728
- Testing
- Bupropion, Varenicline, Smoking Cessation Counseling
- Where
- United States
- Volunteers
- 646 people
- Sponsor
- M.D. Anderson Cancer Center
Smoking, Nicotine Dependence
Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers
The purpose of this study is to determine whether the combination of naltrexone (Depade) and varenicline (Chantix) minimizes post-smoking cessation weight gain and how well the combination is tolerated.
- Trial name
- NCT00502216
- Testing
- Naltrexone, Varenicline
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Yale University